Artivion’s sharp selloff masks a rare MedTech pure-play with monopoly-like aortic arch assets, near-term leverage risk, and potentially powerful 2027 growth catalysts.
Overview
Artivion is a specialized MedTech company transformed from CryoLife into an aortic pure-play focused on life-saving devices and tissues for complex cardiothoracic and vascular procedures. Revenue is led by high-growth aortic stent grafts and On-X mechanical valves, supported by BioGlue and preservation services. Its products win through strong clinical data, regulatory differentiation, and surgeon adoption in demanding procedures. FY2025 revenue reached $441.3 million, up 13.6%, with aortic stent grafts growing 29.5% and On-X valves growing 21.1%, underscoring a mix shift toward higher-growth franchises.